Advanced in Cholangiocarcinoma (Bile Duct Cancer)

Dr. Theodore W. Pollock

Hematology Oncology | Oncology
Northeastern Health System
1400 E Downing St, 
Tahlequah, OK 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Northeastern Health System
1400 E Downing St, 
Tahlequah, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Theodore Pollock is a Hematologist Oncology specialist and an Oncologist in Tahlequah, Oklahoma. Dr. Pollock is rated as an Advanced provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Anal Cancer, and Familial Colorectal Cancer. Dr. Pollock is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Cholangiocarcinoma (Bile Duct Cancer).

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Northeastern Health System
Cherokee Nation W W Hastings Indian Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

NORTHEASTERN HEALTH SYSTEM
1400 E Downing St, Tahlequah, OK 74464

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

3 Total Publications

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Journal: JAMA oncology
Published: June 04, 2021
Similar Doctors
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel W. Mackey
Hematology Oncology | Hematology | Oncology
Advanced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Daniel W. Mackey
Hematology Oncology | Hematology | Oncology

Mercy Clinic Fort Smith Communities

7301 Rogers Ave, 
Fort Smith, AR 
 (51.2 miles away)
479-314-5175
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Mackey is a Hematologist Oncology specialist and a Hematologist in Fort Smith, Arkansas. Dr. Mackey is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Chronic Familial Neutropenia, Paget Disease of the Breast, Neuroendocrine Tumor, and Breast Cancer. Dr. Mackey is currently accepting new patients.

Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Brooke E. Brander
Hematology Oncology | Hematology | Oncology
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Brooke E. Brander
Hematology Oncology | Hematology | Oncology

Highlands Oncology Group PA

3232 N Northhills Blvd, Highlands Oncology Grp Par, 
Fayetteville, AR 
 (46.3 miles away)
479-587-1700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brooke Brander is a Hematologist Oncology specialist and a Hematologist in Fayetteville, Arkansas. Dr. Brander is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Testicular Yolk Sac Tumor, Sertoli-Leydig Cell Tumor, and Bone Marrow Aspiration. Dr. Brander is currently accepting new patients.

Stephan B. Rosenfeld
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Stephan B. Rosenfeld
Hematology Oncology | Oncology | Hematology
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Dr. Stephan B. Rosenfeld
Hematology Oncology | Oncology | Hematology

Highlands Oncology Group PA

3232 N Northhills Blvd, Highlands Oncology Grp Par, 
Fayetteville, AR 
 (46.3 miles away)
479-587-1700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephan Rosenfeld is a Hematologist Oncology specialist and an Oncologist in Fayetteville, Arkansas. Dr. Rosenfeld is rated as a Distinguished provider by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, Gastrostomy, and Bone Marrow Aspiration. Dr. Rosenfeld is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pollock's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 111 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile